Ohio Administrative Code › Title 4731 - State Medical Board › Chapter 4731-11 - Controlled Substances › Section 4731-11-04 - Controlled substances for the treatment of obesity

Current through all regulations passed and filed through July 1, 2024
(A)
								A prescriber may utilize a schedule III or IV
			 controlled substance for the treatment of obesity only if it has an F.D.A
			 approved indication for this purpose and then only in accordance with all of
			 the provisions of this rule.
(B)
								Before initiating
			 treatment for obesity utilizing any schedule III or IV controlled substance,
			 the prescriber shall complete all of the following requirements:
(1)
									The prescriber
			 shall review the prescriber's own records of prior treatment or review the
			 records of prior treatment by another treating physician, prescriber,
			 dietitian, or weight-loss program to determine the patient's past efforts to
			 lose weight in a treatment program utilizing a regimen of weight reduction
			 based on nutritional counseling, intensive behavioral therapy, and exercise,
			 without the utilization of controlled substances, and that the treatment has
			 been ineffective.
(2)
									The prescriber shall complete and document the findings
			 of all of the following:
(a)
										Obtain a thorough history;
(b)
										Perform an
			 appropriate examination of the patient;
(c)
										Determine the
			 patient's BMI;
(d)
										Rule out the existence of any recognized
			 contraindications to the use of the controlled substance to be
			 utilized;
(e)
										Assess and document the patient's freedom from signs of
			 drug or alcohol abuse, and the presence or absence of contraindications and
			 adverse side effects;
(f)
										Access OARRS for the patient's prescription history
			 during the preceding twelve month period and document in the patient's record
			 the receipt and assessment of the report received; and
(g)
										Develop and
			 record in the patient record a treatment plan that includes, at a minimum, a
			 diet and exercise program for weight loss.
(3)
									The prescriber
			 shall not initiate treatment utilizing a controlled substance for the treatment
			 of obesity upon ascertaining or having reason to believe any one or more of the
			 following:
(a)
										The patient has a history of or shows a propensity for
			 alcohol or drug abuse, or has made any false or misleading statement to the
			 prescriber physician related to the patient's use of drugs or
			 alcohol;
(b)
										The patient has consumed or disposed of any controlled
			 substance other than in strict compliance with the treating prescriber's
			 directions;
(c)
										The prescriber knows or should know the patient is
			 pregnant;
(d)
										The patient has a BMI of less than thirty, unless the
			 patient has a BMI of at least twenty seven with comorbid factors, including
			 type 2 diabetes, cardio vascular disease, hypertension, hyperlipidemia,
			 obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis,
			 insulin resistance, metabolic syndrome, pre-diabetes, or major
			 depression;
(e)
										The patient has any condition that would contraindicate
			 the use of the controlled substance to be utilized;
(f)
										The prescriber
			 shall document in the patient's record the rationale for initiation or
			 re-initiation of treatment utilizing a controlled substance for chronic
			 obesity.